Skip to Navigation
Skip to Content

HPV and a Vaccine: Why We Can Beat Cervical Cancer

In 2007, 12,280 women in the United States were told they had cervical cancer, and 4,021 died from the disease.  Here’s the thing: cervical cancer is almost completely preventable.  This means that, given consistent and correct care, you will likely never been one of those 4,000 women who die of this preventable and treatable disease.

 The reason that cervical cancer is almost completely preventable is because, unlike many cancers, which are caused by a number of physical, genetic, lifestyle and environmental factors, almost all cervical cancer is caused by a sexually transmitted virus, the human papillomavirus (HPV).  HPV is very common in the United States— so common that at least 50% of sexually active men and women get it at some point in their lives.  HPV is passed on through skin-to-skin contact during sexual activity with another person, most often during vaginal and anal sex, as well as through oral sex.   There are many different types of HPV and since it usually causes no symptoms (like many STIs), you can get HPV—and pass it on—without realizing it.

 In 90 percent of cases, your own immune system clears HPV naturally within two years.  But, sometimes (and for unknown reasons), HPV infections are not cleared and can cause cervical, anal, vulvar and vaginal cancers as well as genital warts.  There are over 30 types of HPV, but two strains (16 and 18) cause 70 percent of the cervical cancers and are also responsible for most other reproductive cancers.  In addition, two other strains (6 and 11) cause approximately 90 percent of all genital warts.

 But here’s the good news about HPV: there are vaccines currently available that prevent against the types of HPV that can lead to cancer and genital warts.  Let me say that again: there are now two vaccines that can prevent cancer.  Currently on the market are two vaccines approved for women aged 11-26: Gardasil and Cervarix.

In addition, there is an HPV vaccine approved for use in men.  That’s right-- HPV vaccines are not just for girls anymore!  Gardisal is now approved for males under 26.  While they cannot get cervical cancer, HPV can cause genital warts in men, as well as cancer of the penis, anus, or oropharynx (back of the throat).   Men who have sex with men, as is the case with many STIs, are at an increased risk of HPV-related disease.   

Now many of us may get a little squeamish about the idea of preventing an STI in a pre-teen, even if it is one that is both prevalent and linked to cancer.  But here’s the rub: a vaccine cannot prevent against something a patient already has.  As a result, HPV vaccines offer the greatest health benefits to individuals who receive all three doses long before having any type of sexual activity.  That’s why HPV vaccination is recommended for preteen girls and boys at age 11 or 12 years.

Both vaccines are administrated in a three-shot series over a six month time frame.  It is vitally important that individuals complete the full three shot series.  Only through the full three shots will women and men receive the full cancer protection of the vaccine.  Research released in December 2010 found that only 14% of girls and women who start the series finish within the recommended time period.  This research also found that women of color and those who do not have private insurance were less likely to receive all three shots compared to white women and women with private health coverage.  These facts are disappointing and threaten to decrease the promise of a vaccine to cut cancer, particularly in reducing the existing disparities that currently exist in cervical cancer.

While the vaccine is a huge step in fighting a preventable and treatable cancer, it is not the end-all be-all in cervical cancer care.  There are over 30 types of HPV and the vaccines only protect against two or four strains, respectively.  There are still other strains of HPV that cause cancer, and it is possible that a woman could already be infected by HPV when she was vaccinated.   As a result, even with vaccination routine Pap tests or other cervical cancer screening tests are still necessary.

The National Coalition of STD Directors, and its member health department sexually transmitted disease project areas across all 50 states, seven large cities and eight US territories, are key partners in the fight against cervical cancer as well as other reproductive cancers.  State and local STD programs are a key location to receive the vaccine.  I encourage you to visit our website (www.ncsddc.org) to find a site for STD testing and the HPV vaccine near you. 

While we have come a long way, access to the vaccine continues to be a concern.  There are programs such as the Vaccines for Children program to assist those in need, but a full series of the shot retails for approximately $390, according to the Centers for Disease Control and Prevention.  Along with increasing the completion of all three shots, ensuring resources are available to those who find this cost out of reach is vital to ending cervical cancer as we know it in this country.

But this is the bottom line: cervical cancer is one fight we can win.  Today. 

William Smith

Executive Director

National Coalition of STD Directors

  

The National Coalition of STD Directors (NCSD) is a partnership of public health professionals dedicated to promoting sexual health through the prevention of STDs. NCSD provides dynamic leadership that strengthens STD Programs by advocating for effective policies, strategies, and sufficient resources and by increasing awareness of their medical and social impact. 

For more information, visit www.NCSDDC.org. 



This was written as part of The National Latina Institute for Reproductive Health’s Blog Carnival for Cervical Cancer Awareness Month.  For more information, please visit: http://latinainstitute.wordpress.com/.

Highlighted Resources

The National Coalition of STD Directors (NCSD) in partnership with the American Sexually Transmitted Disease Association (ASTDA) hosted a webinar: Point of Care Testing-Where Are We Going?  

Read more...

Sexually transmitted disease (STD) programs do an enormous amount of work to protect the public’s health with continually declining resources. There are many opportunities associated with the evolution of health care in the United States.

Read more...

The National Alliance of State and Territorial AIDS Directors (NASTAD) and the National Coalition of STD Directors (NCSD) are pleased to launch “Addressing Stigma: A Blueprint for HIV/STD Prevention and Care Outcomes for Black and L

Read more...